Neovacs S.A Market cap
What is the Market cap of Neovacs S.A?
The Market cap of Neovacs S.A. is $110.10M
What is the definition of Market cap?
Market capitalization is the market value at a point in time of the shares outstanding of a publicly traded company, being equal to the share price at that point of time times the number of shares outstanding.
= outstanding shares * previous day’s close
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Market cap of companies in the Health Care sector on EURONEXT compared to Neovacs S.A
What does Neovacs S.A do?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Companies with market cap similar to Neovacs S.A
- Wah Wo Hldg Grp Ltd has Market cap of $110.00M
- John Hancock Investors Trust has Market cap of $110.01M
- Generation Mining has Market cap of $110.02M
- Landmark Bancorp Inc has Market cap of $110.05M
- Kings Arms Yard VCT PLC has Market cap of $110.09M
- Proficient Alpha Acquisition has Market cap of $110.09M
- Neovacs S.A has Market cap of $110.10M
- AeroGrow International has Market cap of $110.19M
- Urbana has Market cap of $110.21M
- The Income & Growth VCT has Market cap of $110.22M
- Pioneer Global has Market cap of $110.26M
- Legacy Acquisition has Market cap of $110.28M
- Golden Resources Development International has Market cap of $110.28M